Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sunho Biologics,Inc. ( (HK:2898) ) just unveiled an announcement.
Sunho Biologics, Inc. has scheduled a board meeting for 27 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025 and to authorize their publication. The board will also consider the payment of a final dividend, if any, indicating potential returns for shareholders, while reserving flexibility depending on the company’s financial performance and capital needs.
The meeting will additionally address any other business brought before the directors, underscoring ongoing corporate governance and regulatory compliance for the Hong Kong‑listed biologics group. The announcement also reconfirms the current composition of the board, highlighting the mix of executive, non-executive and independent non-executive directors overseeing the company’s strategic and financial decisions.
The most recent analyst rating on (HK:2898) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Sunho Biologics,Inc. stock, see the HK:2898 Stock Forecast page.
More about Sunho Biologics,Inc.
Sunho Biologics, Inc. is a Cayman Islands-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange. The group focuses on biologics-related activities, operating through a board comprising executive, non-executive and independent non-executive directors as it pursues growth in the life sciences sector.
Average Trading Volume: 9,650
Technical Sentiment Signal: Hold
Current Market Cap: HK$971.9M
For an in-depth examination of 2898 stock, go to TipRanks’ Overview page.